SAN DIEGO, June 5, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech company,
today announced its chief financial officer David Ramsay will retire this summer, and named
biotech veteran Laurie Stelzer as
his successor. Stelzer will assume CFO duties on June 15 and will work with Ramsay through a
transition period.
"Since last year, David and I have been working closely to plan
for his eventual retirement and I am thrilled to now welcome a
finance executive of Laurie's caliber," said Dr. Helen Torley, president and chief executive
officer. "David helped guide Halozyme for more than a decade as the
company built a significant partner model with our ENHANZE™
platform and more recently as we laid the foundation for the
development of our oncology programs. I want to thank him for the
value he has created for our employees and shareholders, and for
being a trusted partner to me.
"As we prepare for the regulatory submissions and
commercialization upon approval of our investigational new drug
PEGH20 in the U.S. and Europe,
Laurie brings unique experience gained by supporting similar
commercial plans at Amgen and Shire."
Most recently at Shire, Stelzer served as senior vice president
of Finance for R&D, Technical Operations and Business
Development, and was previously Division CFO for Regenerative
Medicine. Before Shire, she spent 15 years at Amgen, in senior
leadership roles in finance and business development with
responsibilities including the U.S., Canada and International Markets, ultimately
serving as the company's acting treasurer. In this role, she led a
leveraged recapitalization that included $10
billion in bond offerings and the corresponding expanded
share buyback program, which contributed to an increase in
shareholder value. Stelzer earned her B.S. in Accounting from
Arizona State University and MBA from
the UCLA Anderson School of Management.
"I look forward to joining this growing and dynamic company and
helping it achieve the full potential of PEGPH20 and the ENHANZE
platform," said Stelzer. "I am impressed with the strong management
team Helen has assembled and see a great opportunity to make a
difference in the effectiveness of cancer therapy."
Earlier this week, Halozyme announced a substantial new global
collaboration with drug giant, AbbVie, and presented encouraging
interim data on its phase 2 study of PEGPH20 for the potential
treatment of patients with metastatic pancreatic cancer. Halozyme
plans to initiate its pivotal phase 3 study of PEGPH20 in the first
quarter of 2016.
"As a long-term shareholder, I am proud of the progress the
company has made and will watch with great confidence as Helen,
Laurie and the rest of the team lead the company into the future,"
said Ramsay.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program, an
investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor. PEGPH20
is currently in development for metastatic pancreatic cancer and
non-small cell lung cancer and has potential across additional
cancers in combination with different types of therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Pfizer, Janssen, Baxter and AbbVie for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San
Diego. For more information, visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements that involve risk and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected fluctuations or changes in revenues from collaborators,
unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in the Company's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 11,
2015.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-announces-plans-for-cfo-transition-names-laurie-stelzer-cfo-300094691.html
SOURCE Halozyme Therapeutics, Inc.